Fragment-guided approach to incorporating structural information into a CoMFA study: BACE-1 as an example

Area of Science:

• Medicinal Chemistry
• Computational Drug Discovery
• Neuroscience

Background:

• Alzheimer's disease (AD) is a fatal neurodegenerative disorder.
• Beta-secretase 1 (BACE-1) is a validated therapeutic target for AD.
• Numerous BACE-1 crystal structures are available in the Protein Data Bank (PDB).

Purpose of the Study:

• To develop a novel methodology integrating ligand-based and structure-based approaches for BACE-1 inhibitor design.
• To enhance the predictive accuracy of 3D-Quantitative Structure-Activity Relationship (3D-QSAR) models.
• To identify opportunities for developing more potent BACE-1 inhibitors.

Main Methods:

• A new fragment-guided approach was developed, combining ligand-based methods with structural information from BACE-1 receptor complexes.
• Comparative analysis with other molecular alignment methods, including docking.
• Investigation of the impact of different partial charge calculation methods on model performance.

Main Results:

• Several consistent and predictive 3D-QSAR models were generated, with one achieving r²=0.88, q²=0.69, and r(pred)²=0.72.
• The novel methodology demonstrated superior performance compared to other approaches, especially in external predictive power.
• Contour map analysis revealed potential sites for analog design to improve inhibitor potency.

Conclusions:

• The presented fragment-guided methodology effectively integrates diverse data for improved 3D-QSAR studies.
• This approach offers enhanced predictive capabilities for designing potent BACE-1 inhibitors.
• The findings suggest a promising direction for accelerating Alzheimer's disease therapeutic development.